Desmopressin
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Synthetic vasopressin (ADH) analog with selective V2 receptor agonism; FDA-approved for central diabetes insipidus, nocturnal enuresis, hemophilia A, and von Willebrand disease.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | DDAVP, Stimate, Nocdurna, Minirin, 1-desamino-8-D-arginine vasopressin, dDAVP |
| Category | Endocrine / Hematologic |
| Sequence | Mpa-Tyr-Phe-Gln-Asn-Cys-Pro-D-Arg-Gly-NH2 (disulfide bond between Mpa1-Cys6; deaminated N-terminus) |
| Molecular Weight | ~1069 Da |
| Molecular Formula | C46H64N14O12S2 |
| PubChem CID | 5311065 |
| Administration | Intranasal spray, oral tablet, oral lyophilisate (melt), SubQ, IV |
| Typical Dose Range | 10-40 mcg intranasal; 0.1-0.4 mg oral tablet; 0.3 mcg/kg IV/SubQ (hemostatic use) |
| Half-Life | ~1.5-2.5 hours (intranasal); ~2-3 hours (oral); ~3 hours (IV) |
| Storage | Room temperature (oral); refrigerated (nasal spray, injectable) |
| FDA Status | Approved (1978) — DDAVP/Stimate/Nocdurna for central diabetes insipidus, nocturnal enuresis, hemophilia A (mild), von Willebrand disease (Type 1) |
| WADA Status | Not prohibited (FDA-approved medication) |
Mechanism of Action
Desmopressin is a synthetic analog of arginine vasopressin (AVP/ADH) with two key structural modifications: (1) deamination of the N-terminal cysteine (creating 1-desamino) and (2) substitution of L-arginine with D-arginine at position 8. These modifications produce two critical pharmacological changes: selective V2 receptor agonism with minimal V1 receptor activity (eliminating the vasopressor effect), and enhanced proteolytic resistance extending the half-life to 2-3 hours (vs ~10-20 minutes for native vasopressin).
Antidiuretic action: V2 receptor activation on renal collecting duct principal cells triggers a Gs/cAMP/PKA signaling cascade that phosphorylates aquaporin-2 (AQP2) water channels, promoting their translocation from intracellular vesicles to the apical membrane. This dramatically increases water permeability of the collecting duct, enabling water reabsorption from the tubular lumen and concentrating the urine. This mechanism directly addresses the water-losing state in central diabetes insipidus (deficient endogenous ADH) and reduces nocturnal urine production in enuresis (PMID: 40728007).
Hemostatic action: V2 receptors are also expressed on vascular endothelial cells. Desmopressin activates endothelial V2 receptors, triggering cAMP-mediated exocytosis of Weibel-Palade bodies — specialized secretory granules containing von Willebrand factor (vWF) and tissue plasminogen activator (tPA). The released vWF carries Factor VIII, raising plasma levels of both vWF and Factor VIII 2-6 fold within 30-60 minutes. This mechanism is therapeutically exploited in mild hemophilia A (baseline Factor VIII >5%) and Type 1 von Willebrand disease, providing a non-transfusional hemostatic option that avoids infection and inhibitor risks of plasma-derived products (PMID: 29491128).
Tachyphylaxis: Repeated doses within 24-48 hours produce diminished responses (tachyphylaxis) due to depletion of endothelial vWF/Factor VIII stores. A minimum 48-hour interval between hemostatic doses is recommended to allow store replenishment.
Key Research Areas
- Nocturnal enuresis in children — Cochrane review confirms ~70% response rate (complete or significant reduction in wet nights); best results in children >10 years with nocturnal polyuria; 50-60% relapse after discontinuation (PMID: 40728007)
- Combination therapy for enuresis — Network meta-analysis of 18 RCTs (n=1649) shows desmopressin + alarm is the most effective strategy; desmopressin + anticholinergic ranks second (PMID: 30216627)
- Hemostatic therapy — Nearly 50 years of clinical experience validates desmopressin as first-line for mild hemophilia A and Type 1 vWD, raising Factor VIII 2-6 fold via endothelial V2R activation (PMID: 29491128)
- Central diabetes insipidus — Gold standard replacement therapy for ADH deficiency
- Surgical/procedural hemostasis — Used pre-operatively to reduce bleeding in mild coagulation disorders
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Systematic reviews | 2 | Cochrane enuresis review; network meta-analysis |
| Human RCTs | 0 | (Included within systematic reviews above) |
| Human observational | 0 | — |
| Animal in vivo | 0 | — |
| In vitro | 0 | — |
| Narrative reviews | 1 | Mannucci hemophilia review (50 years of experience) |
Clinical Applications
- Central diabetes insipidus — Replacement therapy for ADH deficiency
- Nocturnal enuresis — First-line pharmacological treatment in children
- Mild hemophilia A — Non-transfusional hemostatic therapy
- Von Willebrand disease (Type 1) — vWF/Factor VIII release from endothelial stores
Protocols Using This Peptide
- No current vault protocols use desmopressin (FDA-approved prescription medication, not a research peptide)
Ageless Peps Products
- Not sold by Ageless Peps. Desmopressin is an FDA-approved prescription medication (DDAVP/Stimate/Nocdurna) available only through licensed pharmacies.
Dosing Reference
FDA-Approved Dosing
| Indication | Dose | Route | Frequency | Duration | Source |
|---|---|---|---|---|---|
| Central diabetes insipidus | 10-40 mcg | Intranasal | 1-3 times daily | Ongoing | FDA label |
| Central diabetes insipidus | 0.1-0.8 mg | Oral | 2-3 times daily | Ongoing | FDA label |
| Nocturnal enuresis (children >=6 yrs) | 0.2-0.6 mg | Oral tablet | Once at bedtime | Weeks-months | FDA label |
| Nocturnal enuresis | 20-40 mcg | Intranasal | Once at bedtime | Weeks-months | FDA label |
| Nocturia (adults) | 27.7-55.3 mcg | Sublingual melt (Nocdurna) | Once at bedtime | Ongoing | FDA label |
| Hemophilia A / vWD (hemostatic) | 0.3 mcg/kg | IV (over 15-30 min) | Single dose pre-procedure | As needed | FDA label |
| Hemophilia A / vWD (hemostatic) | 300 mcg (one spray each nostril) | Intranasal (Stimate 1.5 mg/mL) | Single dose pre-procedure | As needed | FDA label |
Cycling
Desmopressin is not cycled in the traditional sense. For diabetes insipidus, it is used continuously as replacement therapy. For nocturnal enuresis, structured withdrawal protocols (gradual dose reduction over weeks) are recommended to reduce relapse rates. For hemostatic use, a minimum 48-hour interval between doses is needed to prevent tachyphylaxis from endothelial store depletion.
Contraindications & Safety
- Contraindications: Hyponatremia or history of hyponatremia, polydipsia (habitual or psychogenic), moderate-severe renal impairment (CrCl <50 mL/min for some formulations), concomitant loop diuretics or systemic/inhaled glucocorticoids (Nocdurna)
- Critical safety concern — Hyponatremia: The most serious adverse effect. Water retention without electrolyte retention can cause dilutional hyponatremia, which may progress to seizures, coma, and death if severe. Fluid restriction is mandatory during desmopressin use (limit intake to minimum necessary). Serum sodium should be monitored, especially in children and elderly.
- Common side effects: Headache, nausea, nasal congestion/rhinitis (intranasal), abdominal cramps, facial flushing
- Drug interactions: Loop diuretics (enhance hyponatremia risk), carbamazepine/chlorpropamide/SSRIs (enhance ADH effect, increase hyponatremia risk), lithium (reduces desmopressin efficacy)
- Pregnancy/nursing: Category B; used clinically in pregnancy for diabetes insipidus and vWD
- Special populations: Elderly at higher risk of hyponatremia; children require close sodium monitoring; renal impairment increases risk
Synergistic Combinations
- Desmopressin is used as monotherapy for its primary indications
- In enuresis: combination with alarm therapy or anticholinergics improves outcomes vs desmopressin alone (PMID: 30216627)
- In hemophilia: may be combined with tranexamic acid (antifibrinolytic) for mucosal bleeding procedures
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 40728007 | Desmopressin for Nocturnal Enuresis in Children (Cochrane) | 2025 | Systematic Review |
| 30216627 | Desmopressin vs Alarm in Paediatric Nocturnal Enuresis: Network Meta-Analysis | 2018 | Meta-analysis |
| 29491128 | Use of Desmopressin in Hemophilia A: Towards a Golden Jubilee | 2018 | Narrative Review |
References
- PMID: 40728007 — Cochrane Review, desmopressin for nocturnal enuresis (2025)
- PMID: 30216627 — Network meta-analysis, enuresis treatment strategies (2018)
- PMID: 29491128 — Mannucci, hemophilia A review (2018)
Related
- Peptide Index
- Condition Index
- Research Index
- Oxytocin — Related posterior pituitary peptide (9 amino acids, differs by 2 residues from vasopressin)
#peptide #fda-approved #not-sold #intranasal #oral #subq